ABCSG 60 / CAMBRIA-1 Overview
A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with camizestrant versus standard endocrine therapy in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed at least 2 years of standard adjuvant endocrine-based therapy without disease recurrence.
| Start: | (global): 03/2023; FPI 04/2023 (national): 07/2023 |
| Coordinating Investigator AT: | Daniel Egle, Innsbruck |
| Sample: | 4300 (global), 100 (national) |
| Study design: (Click to enlarge) |
 |
Share on